Tempus AI, Inc. - Class A Common Stock (NQ: TEM)
This article provides a list of recent news headlines, press releases, and research articles related to Tempus AI, Inc. (Nasdaq: TEM). It highlights various developments including new investments, product validations, financial results, and analyst coverage, emphasizing the company's growth and activities in the AI healthcare sector.
Vanguard disaggregates holdings; reports 0 shares of Tempus AI (TEM)
Vanguard has filed an amendment to its Schedule 13G/A, reporting zero beneficial ownership of Tempus AI (TEM) common stock. This change is due to an internal realignment within The Vanguard Group, where certain subsidiaries will now report their beneficial ownership separately. The filing emphasizes that this is an administrative reporting change and not an economic sale or acquisition of Tempus AI shares.
Lefkofsky Eric P, CEO of Tempus AI, sells $7.7 million in stock
Eric P. Lefkofsky, CEO of Tempus AI (NASDAQ:TEM), sold 151,520 shares totaling $7.7 million on March 26, 2026, through entities he manages. Despite the stock's 28% year-to-date decline, Tempus AI reported strong Q4 earnings, surpassing analyst expectations with 83% revenue growth. The company also expanded its collaboration with Merck, leading to mixed analyst price target adjustments.
# Lefkofsky Eric P, CEO of Tempus AI, sells $7.7 million in stock
Eric P. Lefkofsky, CEO of Tempus AI, has sold 151,520 shares of Class A Common Stock for approximately $7.7 million. These sales were executed through entities he manages, following a Rule 10b5-1 trading plan. Despite the stock's 28% year-to-date decline, Tempus AI recently surpassed Q4 earnings expectations with significant revenue growth in its Diagnostics and Data segments and announced an expanded collaboration with Merck.
Lefkofsky Eric P, CEO of Tempus AI, sells $7.7 million in stock
Eric P. Lefkofsky, CEO of Tempus AI, Inc., sold 151,520 shares of Class A Common Stock for approximately $7.7 million on March 26, 2026, through indirect entities. Despite the sale, he maintains significant indirect holdings in the company. This transaction occurred amidst a 28% year-to-date decline in the stock's price, following a strong fourth-quarter earnings report where Tempus AI surpassed analyst expectations and announced an expanded collaboration with Merck.
Tempus AI (TEM) CEO-linked entities sell 166K shares under 10b5-1 plan
Entities linked to Tempus AI (TEM) CEO Eric P. Lefkofsky sold 166,250 shares of Class A Common Stock on March 26, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were made at weighted average prices ranging from approximately $45.78 to $47.42. Despite these sales, Lefkofsky-linked entities Gray Media, LLC and Blue Media, LLC, along with other direct and indirect holdings, retain significant ownership in Tempus AI.
Tempus AI (NASDAQ: TEM) insiders and affiliates report Class A stock sales
Tempus AI, Inc. (NASDAQ: TEM) has reported proposed and recent sales of Class A Common stock via a Form 144 filing. The filing indicates transactions by insiders and affiliates, including Eric Lefkofsky and entities like Blue Media, LLC and Gray Media, LLC, with specific share counts and dates provided for both past sales and intended dispositions. The document also details the acquisition and payment history for some of the securities being sold.
Cathie Wood Chooses Medical AI Over Mark Zuckerberg: Ark Loads Up On TEM Stock, Dumps Meta Shares
Cathie Wood's Ark Invest made significant trades, including increasing its holdings in Tempus AI Inc (TEM) due to its collaboration with Daiichi Sankyo for AI-driven biomarker discovery in oncology. Concurrently, Ark divested Meta Platforms Inc (META) shares amid Meta's legal challenges and layoffs. The firm also sold shares in Archer Aviation Inc (ACHR) and Block Inc (XYZ), while making other strategic adjustments in various companies.
Tempus AI (Nasdaq:TEM) - Stock Analysis
This article provides a stock analysis of Tempus AI (Nasdaq:TEM), a healthcare technology company specializing in genomics and data platforms. It highlights the company's current valuation, future growth prospects, past performance, financial health, and dividend policy, along with recent news and analyst narratives. The analysis suggests Tempus AI is trading significantly below its estimated fair value but is currently unprofitable, despite strong projected revenue growth.
Tempus AI, Inc. Class A Trade Ideas — BX:TEM
This article compiles various trade ideas and analyses for Tempus AI, Inc. (TEM). Several contributors offer insights ranging from technical analysis to fundamental assessments, with most presenting a "Buy" rating based on the company's strong growth potential in the AI healthcare market, strategic partnerships, and financial performance. The article also provides a detailed strategy for utilizing call options and outlines associated risks and risk management techniques.
Tempus AI CFO Sells Over 11K Shares
Rogers James William, the Chief Financial Officer of Tempus AI (TEM), sold 11,414 shares of Class A Common Stock on March 2, 2026. The transaction totaled $578,575 at a price of $50.69 per share and was conducted under a Rule 10b5-1 trading plan. Following this sale, the CFO still directly owns 127,248 shares of the company.
Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
Two lawsuits have been filed against Tempus AI, Inc. in the U.S. District Court for the Northern District of Illinois, alleging violations of the Illinois Genetic Information Privacy Act. The lawsuits stem from Tempus AI's acquisition of Ambry Genetics and the subsequent integration of its genetics data into Tempus's predictive models. This raises critical questions about proper consent for data use, especially concerning the concept of "de-identified" versus "de-identifiable" germline DNA data in the rapidly advancing field of AI and genomics.
Tempus AI (TEM) Is Down 6.9% After Raising 2026 Outlook And Filing ESOP Shelf Offering
Tempus AI (TEM) saw its stock drop by 6.9% despite reporting stronger 2025 results, raising its 2026 revenue guidance to approximately US$1.59 billion, and launching a new oncology algorithm. The company also filed a US$343.38 million Class A common stock shelf registration related to an ESOP offering. While these updates signal rapid top-line growth and narrowing losses, investors are balancing the company's significant investment in AI-driven diagnostics against ongoing risks like reimbursement and competition.
Director David R. Epstein sells Tempus AI (TEM) shares under 10b5-1 plan
Tempus AI director David R. Epstein sold 250 shares of Class A Common Stock at $50.69 per share on March 2, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in August 2024. Following this transaction, Epstein directly holds 25,801 shares. This insider trade was reported via a SEC Form 4 filing, indicating a neutral filing impact but negative sentiment.
Tempus AI (TEM) CFO executes 11,414-share planned sale under Rule 10b5-1 plan
Tempus AI's Chief Financial Officer, James William Rogers, sold 11,414 shares of Class A common stock at an average price of $50.69 per share on March 2, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 11, 2025. Following the sale, Mr. Rogers directly owns 127,248 shares of Tempus AI.
What Does the Market Think About Tempus AI Inc?
Tempus AI Inc's short interest has increased by 5.6% since its last report, with 22.73 million shares sold short, representing 17.72% of its tradable shares. This elevated short interest suggests a more bearish sentiment from investors compared to its peers, whose average short interest is 7.61%. It would take traders approximately 4.04 days to cover their short positions, indicating significant market attention on the stock.
Guggenheim Remains a Buy on Tempus AI, Inc. Class A (TEM)
Guggenheim reiterated a Buy rating for Tempus AI, Inc. Class A (TEM) with a price target of $95.00, while Morgan Stanley also maintained a Buy rating with an $85.00 price target. The company posted strong quarterly revenue of $334.21 million, though it reported a GAAP net loss of $79.98 million. Corporate insider sentiment is currently negative, with increased insider selling over the past quarter.
TEM SEC Filings - Tempus AI 10-K, 10-Q, 8-K Forms
This page provides access to Tempus AI (TEM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It highlights recent filings such as the Q2 2025 10-Q detailing doubled revenue and narrowed losses, an S-3ASR filing for a $500M at-the-market facility, and S-8 amendments reflecting reincorporation to Nevada. The platform also offers AI-powered summaries of these regulatory documents.
Expert Outlook: Tempus AI Through The Eyes Of 6 Analysts
Six analysts recently assessed Tempus AI (NASDAQ: TEM), with ratings ranging from bullish to indifferent, leading to an average 12-month price target of $82.33, a decrease from the previous average. The company shows strong revenue growth of 84.72% as of September 30, 2025, but faces challenges with below-industry average net margin, ROE, and ROA, alongside a higher-than-average debt-to-equity ratio. Analysts update their ratings and price targets based on market dynamics, company performance, and financial data, providing investors with insights into the stock's potential.
TEM SEC Filings - Tempus AI 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Tempus AI (TEM) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights insider trading activities with specific examples of Form 144 and Form 4 filings, detailing proposed and actual sales of Class A common stock by executives and directors. The page also mentions updates to the company's charter and provides market data for Tempus AI.
What's Next: Tempus AI's Earnings Preview
Tempus AI (NASDAQ: TEM) is scheduled to release its quarterly earnings on Tuesday, February 24, 2026. Analysts anticipate an earnings per share (EPS) of $-0.14. Investors will be looking for the company to surpass estimates and provide positive guidance, as past earnings results have shown varied stock price reactions.
[Form 3] Tempus AI, Inc. Initial Statement of Beneficial Ownership
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI, Inc., reported initial beneficial ownership of 94,967 shares of Class A common stock. This includes 54,405 restricted stock units with vesting scheduled through February 15, 2028, and 20,000 performance-based stock units certified on February 20, 2026, which are set to vest on August 15, 2026. The filing indicates a neutral impact and sentiment on this insider transaction.
Tempus AI (TEM) Loss Deepens To US$0.30 EPS As Premium Valuation Thesis Faces Test
Tempus AI (TEM) reported a Q4 2025 revenue of US$367.2 million and a basic EPS loss of US$0.30, with a net income loss of US$54.2 million. Despite robust revenue growth and biopharma partnerships, the company continues to incur significant losses, prompting questions about its ability to convert revenue into profitability. Analysts foresee 29.7% annual revenue growth over the next three years but do not expect profitability during that period, challenging the premium 7.5x P/S valuation compared to peers.
Tempus AI Reports Strong Q4 Growth and Positive EBITDA
Tempus AI, Inc. announced robust growth for Q4 and the full year 2025, with revenue reaching $1.27 billion, an 83.4% increase year-over-year. The company achieved positive adjusted EBITDA of $12.9 million in Q4 2025 and provided strong 2026 guidance, projecting $1.59 billion in revenue and $65 million in adjusted EBITDA, signaling a path toward higher-margin growth. Despite weak profitability and high leverage, strategic advancements like the launch of Paige Predict and expanded collaborations underpin their future prospects.
Tempus AI Stock Drops Despite Q4 Earnings Beat: Details
Tempus AI (NASDAQ: TEM) shares experienced a decline in extended trading despite surpassing both revenue and earnings estimates in its fourth-quarter report. The company reported quarterly losses of four cents per share, in line with consensus, and revenue of $367.21 million, exceeding estimates. Tempus AI highlighted strong growth in diagnostics revenue, particularly in oncology and hereditary testing, and significant growth in its data and applications segment, setting a fiscal 2026 revenue outlook of $1.59 billion.
Tempus AI EVP sells 9,464 shares in plan trade | TEM SEC Filing - Form 4
Tempus AI (TEM) Executive Vice President Erik Phelps sold a total of 9,464 Class A common shares on February 19, 2026, through a combination of a pre-established Rule 10b5-1 trading plan and sales to cover tax obligations from restricted stock unit vesting. The shares were sold at prices around $60.00 and $59.05, with a portion ranging from $58.71 to $59.38. Following these transactions, Phelps retains between 79,816 and 85,466 shares of the company.
Tempus AI EVP Erik Phelps Sells Shares
Erik Phelps, EVP and Chief Administrative Officer of Tempus AI, sold 9,464 shares of Class A Common Stock on February 19, 2026, for a total of $562,472. The sales were executed through a pre-arranged 10b5-1 trading plan and to cover tax withholding obligations on vested restricted stock units. Following these transactions, Phelps directly owns 79,816 shares of Tempus AI.
Tempus AI CEO Lefkofsky sells shares worth $10.5 million
Tempus AI CEO Eric P. Lefkofsky sold approximately $10.5 million worth of Class A Common Stock on February 19, 2026, through a 10b5-1 trading plan and for tax obligations. The sales occurred as TEM stock reached $58.37, down 44% from its 52-week high. Concurrently, Lefkofsky acquired 263,430 shares through vested restricted stock units comprising his 2025 bonus award.
Tempus AI (TEM) CFO reports share grant and mandatory tax-cover sale
Tempus AI's CFO, James William Rogers, reported receiving a grant of 37,496 Class A common shares at no cost, which included fully vested restricted stock units and earned performance-based stock units. Concurrently, he sold 10,084 shares at a weighted average price of $59.05 per share. This sale was a mandatory "sell to cover" transaction to fulfill statutory tax withholding obligations associated with the vesting of restricted stock units, and not a discretionary sale by the CFO.
Looking Into Tempus AI Inc's Recent Short Interest
Tempus AI Inc's (NYSE: TEM) short interest has increased by 6.65% since its last report, with 21.40 million shares sold short, representing 16.68% of its tradable shares. This elevated short interest, which is higher than its peer group average of 6.71%, suggests a more bearish sentiment among investors towards the company. Short interest is an important indicator for gauging market sentiment, as growing short positions often signal that investors anticipate a stock's price to decline.
Tempus AI IPS Study Points To Wider Immunotherapy Use And Investor Interest
Tempus AI (NasdaqGS:TEM) announced new study results for its Immune Profile Score (IPS) test, which showed improved prediction of immunotherapy outcomes compared to conventional biomarkers. This could expand access to immune checkpoint inhibitor therapy and has attracted investor interest due to its potential in diagnostics, oncology, and AI-enabled clinical decision support. The company's IPS update aligns with its strategy to leverage rich oncology data and AI for growth, however, challenges include profitability, reimbursement, and competition from larger diagnostic players.
How Is The Market Feeling About Tempus AI Inc?
Tempus AI Inc's short interest has increased by 10.84% since its last report, with 20.07 million shares sold short, representing 15.64% of its float. This rise indicates a more bearish sentiment among investors compared to the last report. The company's short interest is significantly higher than its peer group average of 6.33%, suggesting a notable level of negative market sentiment.
Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance and Financial Results
The article discusses recent excitement surrounding Tempus AI, Inc. (TEM) due to its FDA 510(k) clearance for AI-driven diagnostic tools, particularly in oncology, despite a recent 9% stock price drop. It highlights impressive preliminary 2025 revenue of $1.27 billion and details significant insider selling activity, hedge fund movements, government contracts, and positive analyst ratings with a median price target of $87.0.
Stock Market Today: Dow Jones, S&P 500 Futures Tumble As DOJ Serves Federal Reserve—Vistra, Tempus AI, Alibaba In Focus
U.S. stock futures declined on Monday, influenced by rising tensions between the Department of Justice and the Federal Reserve regarding Chairman Jerome Powell's testimony, and a slight miss on nonfarm payrolls. Despite the market dip, several individual stocks including Vistra, Alibaba, Tempus AI, and Xpeng saw premarket gains due to positive company-specific news. Upcoming economic data releases and analyst insights, particularly from Mohamed El-Erian, suggest continued market volatility and a focus on inflation trends and the geopolitical landscape.
Tempus AI Reports Strong Preliminary 2025 Revenue Growth
Tempus AI reported strong preliminary unaudited financial results for the full year and fourth quarter ended December 31, 2025. The company saw an 83% year-over-year revenue increase to approximately $1.27 billion for the full year, driven by significant growth in both its Diagnostics and Data and Applications segments. Management highlighted 2025 as an exceptional year, with both core product lines entering 2026 with accelerating growth and improving financial leverage, reinforcing Tempus AI's position in AI-driven precision medicine.
Tempus AI’s Earnings Call Highlights Strong Growth Amid Challenges
The provided content is empty, so a summary cannot be generated. This indicates an error in the input content, as no article text was found.
Fukushima, Tempus AI COO, sells $321k in shares By Investing.com
Ryan Fukushima, COO of Tempus AI (NASDAQ:TEM), sold 5,000 shares for $321,300 on January 5, 2026, under a Rule 10b5-1 trading plan. Despite the sale, Tempus AI shares have climbed, reflecting strong momentum and an 18% gain over the past week, though InvestingPro analysis suggests the stock is overvalued. The company recently reported better-than-expected Q3 2025 earnings and announced a partnership with the Institute for Follicular Lymphoma Innovation.
Fukushima, Tempus AI COO, sells $321k in shares
Ryan Fukushima, COO of Tempus AI (NASDAQ:TEM), sold 5,000 shares for $321,300 on January 5, 2026. This sale occurred under a Rule 10b5-1 trading plan, despite the stock showing strong momentum with an 18% gain over the past week. Tempus AI recently exceeded Q3 2025 earnings and revenue expectations, although its stock declined post-earnings due to future guidance concerns, leading to mixed analyst price target adjustments.
Fukushima, Tempus AI COO, sells $321k in shares By Investing.com
Ryan Fukushima, COO of Tempus AI, sold 5,000 shares for $321,300 on January 5, 2026, under a Rule 10b5-1 plan. Despite the sale, his indirect and direct holdings remain substantial, and Tempus AI's stock has seen an 18% weekly gain and a 79% annual return, though InvestingPro analysis suggests it may be overvalued. The company recently exceeded Q3 2025 earnings and revenue expectations and announced a research partnership.
Fukushima, Tempus AI COO, sells $321k in shares By Investing.com
Ryan Fukushima, COO of Tempus AI, Inc. (NASDAQ:TEM), sold 5,000 shares of Class A Common Stock for $321,300 on January 5, 2026, under a Rule 10b5-1 trading plan. The sale occurred after an 18% stock gain in the preceding week, with Tempus AI's stock showing a strong 79% return over the last year despite InvestingPro analysis suggesting it is overvalued. The company recently reported better-than-expected Q3 2025 earnings and announced a research partnership with the Institute for Follicular Lymphoma Innovation (IFLI).
Fukushima, Tempus AI COO, sells $321k in shares By Investing.com
Ryan Fukushima, COO of Tempus AI, sold 5,000 shares of Class A Common Stock for $321,300 on January 5, 2026. This transaction occurred under a Rule 10b5-1 trading plan, and Fukushima continues to hold a significant number of shares both directly and indirectly. Despite the sale, Tempus AI's stock has seen an 18% gain in the past week, though analysis suggests it may be overvalued.
Fukushima, Tempus AI COO, sells $321k in shares
Ryan Fukushima, Chief Operating Officer of Tempus AI, Inc., sold 5,000 shares of Class A Common Stock worth $321,300 on January 5, 2026. This sale, conducted under a Rule 10b5-1 plan, occurred as Tempus AI (NASDAQ:TEM) shares climbed, showing impressive year-over-year gains despite being considered overvalued by InvestingPro. The company recently exceeded Q3 2025 earnings expectations and announced a research partnership with the Institute for Follicular Lymphoma Innovation.
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - T
Kahn Swick & Foti, LLC (KSF) is reminding investors of Tempus AI, Inc. (NasdaqGS: TEM) who suffered losses exceeding $100,000 of the lead plaintiff deadline on August 12, 2025, in a securities class action lawsuit. The lawsuit alleges that Tempus AI and its executives failed to disclose material information during the Class Period, specifically regarding overstated AI capabilities, aggressive accounting, and issues with management and past financial reporting. Investors who purchased shares between August 6, 2024, and May 27, 2025, are affected.
Tempus AI Options Trading: A Deep Dive into Market Sentiment
Deep-pocketed investors have shown a bearish sentiment towards Tempus AI (NASDAQ: TEM) through significant options trading activity. While 33% of these investors are bullish, 55% have adopted a bearish stance, with price targets ranging from $35.0 to $95.0. This indicates a notable divergence in market expectations for Tempus AI's stock performance.
Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance and Recent Price Drop
Discussions around Tempus AI, Inc. (TEM) stock are focused on the company's recent FDA 510(k) clearance for AI-driven diagnostic tools, viewed as a positive for precision oncology. Despite this, the stock recently dropped 9%, fueling debate about its future direction, especially given significant insider selling by the CEO and other executives. Analysts generally maintain "Buy" ratings with a median price target of $87.0, while institutional investors show mixed activity with some increasing and others decreasing their holdings.
TEM Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Tempus AI, Inc. Class Action
Robbins LLP reminds investors of the lead plaintiff deadline in the class action lawsuit against Tempus AI, Inc. The lawsuit alleges that Tempus AI inflated the value of contract agreements, misrepresented its AI capabilities, and engaged in aggressive billing practices. These issues led to a significant drop in Tempus common stock after a report by Spruce Point Capital Management, LLC.
Tempus AI (TEM) Logs First Non-GAAP Profit And Bullish 2025 Outlook Is The Thesis Evolving?
Tempus AI (TEM) recently reported its first non-GAAP profit for Q3 2025 due to momentum in genomics testing and data services, alongside plans for further FDA submissions. The company also projected significantly higher 2025 revenue and positive adjusted EBITDA, indicating successful operational scaling. This positive financial performance and optimistic outlook are reshaping the investment narrative, with a fair value estimated at $91.42, suggesting a 42% upside.
Tempus AI price target lowered to $80 from $90 at BofA
BofA analyst Michael Ryskin has reduced the price target for Tempus AI (TEM) to $80 from $90, maintaining a Neutral rating on the shares. This adjustment is part of an update for Life Sciences & Diagnostic Tools stocks under BofA's coverage, anticipating a normalization of markets in 2026 and a return to spending by Biopharma companies, which would benefit firms with high R&D exposure.
Bank of America Securities Sticks to Their Hold Rating for Tempus AI, Inc. Class A (TEM)
Bank of America Securities reiterated a Hold rating on Tempus AI, Inc. Class A (NASDAQ: TEM) with a price target of $80.00. This follows similar ratings from other firms, while Morgan Stanley maintained a Buy rating. The company reported increased revenue but also an increased GAAP net loss in its latest quarter, and corporate insider sentiment is negative due to increased selling activity.
Tempus AI, Inc. Class A Common Stock (TEM) Stock Price Today & Analysis
This article provides an analysis of Tempus AI, Inc. (TEM) stock, including its current price, fundamental financials, and corporate information. It also offers a guide on how to buy TEM stock through the Gotrade app, outlines minimum investment requirements, and clarifies the company's dividend policy and market hours for trading.
